Latest Headlines

Latest Headlines

Actavis dons the Allergan monicker after $70B buyout

Three months after closing its blockbuster buyout of drugmaker Allergan, Actavis is from now on doing business under its acquisition's name, elbowing its way into Big Pharma after years of dealmaking.

Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA

Last week, the FDA approved both Valeant's Xifaxan and Actavis' new Viberzi to treat IBS-D. And now, the market will get to watch what Bernstein analyst Ronny Gal deemed an "interesting test" of two company approaches as the pair competes for uptake.

Actavis and Valeant go head-to-head on IBS as FDA OKs 2 new drugs

A little more than a year after Forest Labs bought out Furiex and its experimental irritable bowel syndrome drug eluxadoline in a $1.5 billion deal, Brent Saunders and Forest-buyer Actavis have scored an FDA approval that should surprise no one. And the agency paired the approval with a green light for Valeant's Xifaxan (rifaximin) in IBS, another drug that's been changing hands lately in the frenzy of M&A deals that has been changing the face of the industry.

Who needs a hard switch? Namenda XR ad campaign is already bolstering conversions

​Actavis may have lost its court bid to "hard switch" original Namenda users to Namenda XR, but that's all the more reason to continue its aggressive marketing of the newer one-a-day Alzheimer's pill.

No Namenda hard switch? No problem, Actavis execs say, with Namzaric on the horizon

Actavis hit a hurdle for Alzheimer's blockbuster Namenda when a court nixed its plot to force patients over to a new, long-acting formula. But as the Dublin drugmaker waits for an answer from an appeals court, it's got a backup plan in place--one that's going very well, execs say.

That Namenda hard switch Actavis wants? It could cost HHS $6B

Actavis said last month it stood to lose $200 million in sales if an appeals court didn't let it force patients over to a new, patent-protected version of Alzheimer's treatment Namenda before generics hit. But if it does? The Department of Health and Human Services (HHS) predicts it'll cost the federal government $6 billion at the least.

Actavis keeps its Phase III promise with Molecular Partners' eye drug

Actavis is rolling toward a Phase III trial with an eye treatment licensed from Switzerland's Molecular Partners, following through on a promise made in the lead-up to its $66 billion acquisition of Allergan.

Rhythm rolls into Phase IIb with an Actavis buyout in the balance

Boston biotech Rhythm is advancing its lead drug into Phase IIb under the eye of Actavis, which has inked a deal to buy the gastrointestinal treatment if it likes what it sees.

Next DTC push for Linzess: Spotlight patients, with big salesforce backup

With Actavis and Ironwood's first DTC campaign for GI med Linzess, the goal was to help patients identify irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) by clearly communicating the symptoms. Now that the team is back with its sophomore DTC effort, the goal is to encourage patients to find a solution to their problems. A branded, prescription solution.

Acadia's shifting calendar spurs market-moving takeout rumors

Acadia Pharmaceuticals' shares rocketed up nearly 20% on Tuesday based on some news tied to two investor conferences. But the market wasn't reacting to anything the company said, instead reading into a pair of cancellations and deducing that a buyout might be in the offing.